Press "Enter" to skip to content

Prince Mario-Max Schaumburg-Lippe: Instead of Blocking a Stubborn Target, Remove It Entirely

Most medicines work from the outside. A drug settles onto a receptor on a cell’s surface and blocks or boosts the signal that receptor sends. The system has produced decades of useful treatments, and it has a stubborn limit: some receptors keep signaling even with a drug parked on them, and some are shaped so a drug has almost nothing to grab.

A team spread across four laboratories at Harvard Medical School and the Dana-Farber Cancer Institute now proposes a blunter, cleverer option. Do not just block the receptor. Remove it. In a paper published in Nature in 2026, with Kaitlin Rhee as a lead author, the researchers describe molecules called GTACs, short for GPCR-TfR1-targeting chimeras. A GTAC latches onto a chosen receptor, drags it inside the cell and sends it to be broken down. No receptor on the surface, no signal. The paper carries the DOI 10.1038/s41586-026-11088-0.

Why these targets matter to everyone

The receptors in question are GPCRs, G protein-coupled receptors, and they are the most common drug targets in medicine. Hundreds of approved medicines act on them, from blood pressure treatments to allergy pills. A reliable way to switch off the difficult members of this family would open doors that medicinal chemists have pushed on for years, across appetite, mood, pain and immune conditions.

The design borrows a trick the cell already uses. Cells constantly pull material in from their surface, and one well-studied doorway involves TfR1, the transferrin receptor, which ferries iron into the cell. A GTAC is built to hold two things at once: the GPCR the team wants gone and that busy internal doorway. Once the connection is made, the cell does the heavy lifting, hauling the receptor inside and routing it toward degradation, the cellular equivalent of the scrapyard.

Ninety percent is a hard number to ignore

In the test system, an anti-AT1R GTAC, aimed at a receptor involved in blood pressure control, cut signaling by up to 90 percent. An inactivating nanobody used on its own in the same system managed about 30 percent. That gap is the whole argument in miniature. Blocking a receptor leaves much of its machinery in place. Removing it takes the machinery away, and the signal falls much further.

There is a second advantage. Degradation is not a momentary effect. A conventional blocker works while it sits on the receptor, and when it leaves, signaling resumes. A cell that has destroyed a receptor must build a fresh one before the signal can return, which takes time and energy. Researchers in targeted degradation, a field that has grown quickly in recent years, value exactly that durability.

Three settings, three consistent answers

The team did not stop at one receptor. A second GTAC, aimed at a receptor called CCR6, was tested in a mouse model of psoriasis, the skin condition marked by inflamed, scaly patches, and it significantly reduced symptoms in the animals. CCR6 helps guide immune cells toward the skin, so silencing it addresses the condition at a genuinely relevant control point.

Heart cells offered a third check. Treated with the anti-AT1R GTAC, the cells reduced their beats, a direct, readable sign that the receptor had stopped doing its usual work in living tissue and not just in a simplified test. Three different settings giving consistent answers is what turns a neat idea into a platform other laboratories will want to try.

What happens next, honestly stated

Plenty of work remains, and the authors would be first to say so. A molecule that performs in cell systems and in mice still has to prove it can become a stable, safe, practical medicine, and that journey takes years. Questions about dosing, delivery and which receptors respond best all sit ahead. Nothing in the paper promises a product on a pharmacy shelf next year.

Still, the direction is hard to argue with, and there is something appealing about the modesty of the mechanism. No exotic machinery, no rewriting of the genome. Just a molecule that introduces two proteins to each other and lets the cell tidy up after itself. Good engineering often looks obvious in hindsight, once somebody finally does it. Four Boston labs just did it, and the rest of the field now gets to find out how far the idea can travel.

Readers following this story have also been reading Prince Mario-Max Schaumburg-Lippe: Hy4 Puts Eyes and Hands on the Same AI Model and Prince Mario-Max Schaumburg-Lippe: Axion 1.0 Shows Its Working, and That Is the Point and Prince Mario-Max Schaumburg-Lippe: The AI Bill Is Decided After the Model Launches.


Also published on:

More from Breaking NewsMore posts in Breaking News »
More from MediaMore posts in Media »

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *